NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Corporation (the “Company”) was held on May 12, 2017, for the
following purposes:
|
|
To elect the nominees for director, Charles J. Link, Jr.
M.D., Paolo Pucci and Thomas A. Raffin, nominated by the Board of Directors of the Company (the “Board”), to serve until the 2020 Annual Meeting of Stockholders; |
|
|
To approve, on an advisory basis, the compensation of the
Company’s named executive officers; and |
|
|
To ratify the selection by the Audit Committee of the Board
of KPMG, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017. |
re-elected as directors of the Company and Paolo Pucci was elected
as a director of the Company. The stockholders of the Company
approved, on an advisory basis, the compensation of the Company’s
named executive officers, as set forth in the Company’s definitive
proxy statement, filed with the Securities and Exchange Commission
on March 31, 2017. In addition, the stockholders of the Company
ratified the appointment of KPMG LLP as the Company’s independent
registered public accounting firm for the Company’s fiscal year
ending December 31, 2017. The final voting results on each of the
matters submitted to a vote of stockholders at the 2017 Annual
Meeting are as follows:
|
Election of Directors
|
For
|
Withheld
|
Broker Non-Votes
|
|
|
1.
|
Charles J. Link, Jr. M.D.
|
20,757,724
|
63,540
|
5,710,077
|
|
|
Paolo Pucci
|
19,860,385
|
960,879
|
5,710,077
|
|
|
Thomas A. Raffin
|
20,744,554
|
76,710
|
5,710,077
|
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
||
|
2.
|
Approval, on an advisory basis, of the compensation of
the Company’s named executive officers |
12,801,787
|
7,982,603
|
36,874
|
5,710,077
|
|
For
|
Against
|
Abstentions
|
||
|
3.
|
Ratification of KPMG LLP as independent registered public
accounting firm for the Company’s fiscal year ending December 31, 2017 |
26,419,245
|
84,526
|
27,570
|
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer. NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information
NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session down -0.25 at 16.10 with 460,587 shares trading hands.
